220 related articles for article (PubMed ID: 31985870)
21. Heterogeneity in the half-life of factor VIII concentrate in patients with hemophilia A is due to variability in the clearance of endogenous von Willebrand factor.
Elsheikh E; Lavin M; Heck LA; Larkin N; Mullaney B; Doherty D; Kennedy M; Keenan C; Guest T; O'Mahony B; Fazavana J; Fallon PG; Preston RJS; Gormley J; Ryan K; O'Connell NM; Singleton E; Byrne M; McGowan M; Roche S; Doyle M; Crowley MP; O'Shea SI; Reipert BM; Johnsen JM; Pipe SW; Di Paola J; Turecek PL; O'Donnell JS;
J Thromb Haemost; 2023 May; 21(5):1123-1134. PubMed ID: 36775768
[TBL] [Abstract][Full Text] [Related]
22. Mendelian Randomization Analysis of Hemostatic Factors and Their Contribution to Peripheral Artery Disease-Brief Report.
Small AM; Huffman JE; Klarin D; Sabater-Lleal M; Lynch JA; Assimes TL; Sun YV; Miller D; Freiberg MS; Morrison AC; Rader DJ; Wilson PWF; Cho K; Tsao PS; Chang KM; Smith NL; O'Donnell CJ; de Vries PS; Damrauer SM;
Arterioscler Thromb Vasc Biol; 2021 Jan; 41(1):380-386. PubMed ID: 32847391
[TBL] [Abstract][Full Text] [Related]
23. Leukocyte telomere length and cardiovascular disease in African Americans: The Jackson Heart Study.
Mwasongwe S; Gao Y; Griswold M; Wilson JG; Aviv A; Reiner AP; Raffield LM
Atherosclerosis; 2017 Nov; 266():41-47. PubMed ID: 28950166
[TBL] [Abstract][Full Text] [Related]
24. Influence of blood group, von Willebrand factor levels, and age on factor VIII levels in non-severe haemophilia A.
Rejtő J; Königsbrügge O; Grilz E; Hofer S; Mauracher LM; Gabler C; Schuster G; Feistritzer C; Sunder-Plaßmann R; Quehenberger P; Gebhart J; Ay C; Pabinger I
J Thromb Haemost; 2020 May; 18(5):1081-1086. PubMed ID: 32073230
[TBL] [Abstract][Full Text] [Related]
25. Increasing levels of von Willebrand factor and factor VIII with age in patients affected by von Willebrand disease.
Biguzzi E; Siboni SM; le Cessie S; Baronciani L; Rosendaal FR; van Hylckama Vlieg A; Peyvandi F
J Thromb Haemost; 2021 Jan; 19(1):96-106. PubMed ID: 32998182
[TBL] [Abstract][Full Text] [Related]
26. Genetic determinants of VWF clearance and FVIII binding modify FVIII pharmacokinetics in pediatric hemophilia A patients.
Swystun LL; Ogiwara K; Rawley O; Brown C; Georgescu I; Hopman W; Labarque V; Male C; Thom K; Blanchette VS; Carcao MD; Lillicrap D
Blood; 2019 Sep; 134(11):880-891. PubMed ID: 31350267
[TBL] [Abstract][Full Text] [Related]
27. Whole-exome sequencing of 14 389 individuals from the ESP and CHARGE consortia identifies novel rare variation associated with hemostatic factors.
Pankratz N; Wei P; Brody JA; Chen MH; de Vries PS; Huffman JE; Stimson MR; Auer PL; Boerwinkle E; Cushman M; de Maat MPM; Folsom AR; Franco OH; Gibbs RA; Haagenson KK; Hofman A; Johnsen JM; Kovar CL; Kraaij R; McKnight B; Metcalf GA; Muzny D; Psaty BM; Tang W; Uitterlinden AG; van Rooij JGJ; Dehghan A; O'Donnell CJ; Reiner AP; Morrison AC; Smith NL
Hum Mol Genet; 2022 Sep; 31(18):3120-3132. PubMed ID: 35552711
[TBL] [Abstract][Full Text] [Related]
28. The ABO blood group genotype and factor VIII levels as independent risk factors for venous thromboembolism.
Tirado I; Mateo J; Soria JM; Oliver A; Martínez-Sánchez E; Vallvé C; Borrell M; Urrutia T; Fontcuberta J
Thromb Haemost; 2005 Mar; 93(3):468-74. PubMed ID: 15735796
[TBL] [Abstract][Full Text] [Related]
29. Associations of activated coagulation factor VII and factor VIIa-antithrombin levels with genome-wide polymorphisms and cardiovascular disease risk.
Olson NC; Raffield LM; Lange LA; Lange EM; Longstreth WT; Chauhan G; Debette S; Seshadri S; Reiner AP; Tracy RP
J Thromb Haemost; 2018 Jan; 16(1):19-30. PubMed ID: 29112333
[TBL] [Abstract][Full Text] [Related]
30. Next-generation sequencing of von Willebrand factor and coagulation factor VIII genes: a cross-sectional study in Croatian adult patients diagnosed with von Willebrand disease.
Lapić I; Radić Antolic M; Boban A; Coen Herak D; Rogić D; Zadro R
Croat Med J; 2022 Apr; 63(2):166-175. PubMed ID: 35505650
[TBL] [Abstract][Full Text] [Related]
31. Modulation of factor VIII pharmacokinetics by genetic components in factor VIII receptors.
Lunghi B; Morfini M; Martinelli N; Branchini A; Linari S; Castaman G; Bernardi F
Haemophilia; 2023 Mar; 29(2):479-487. PubMed ID: 36533781
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of von Willebrand factor phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutations.
Boylan B; Rice AS; De Staercke C; Eyster ME; Yaish HM; Knoll CM; Bean CJ; Miller CH;
J Thromb Haemost; 2015 Jun; 13(6):1036-42. PubMed ID: 25780857
[TBL] [Abstract][Full Text] [Related]
33. Population differences in von Willebrand factor levels affect the diagnosis of von Willebrand disease in African-American women.
Miller CH; Dilley A; Richardson L; Hooper WC; Evatt BL
Am J Hematol; 2001 Jun; 67(2):125-9. PubMed ID: 11343385
[TBL] [Abstract][Full Text] [Related]
34. Factor VIII and von Willebrand factor changes after desmopressin and during pregnancy in type 2M von Willebrand disease Vicenza: a prospective study comparing patients with single (R1205H) and double (R1205H-M740I) defect.
Castaman G; Federici AB; Bernardi M; Moroni B; Bertoncello K; Rodeghiero F
J Thromb Haemost; 2006 Feb; 4(2):357-60. PubMed ID: 16420565
[TBL] [Abstract][Full Text] [Related]
35. Plasma Levels of Soluble Interleukin-2 Receptor α: Associations With Clinical Cardiovascular Events and Genome-Wide Association Scan.
Durda P; Sabourin J; Lange EM; Nalls MA; Mychaleckyj JC; Jenny NS; Li J; Walston J; Harris TB; Psaty BM; Valdar W; Liu Y; Cushman M; Reiner AP; Tracy RP; Lange LA
Arterioscler Thromb Vasc Biol; 2015 Oct; 35(10):2246-53. PubMed ID: 26293465
[TBL] [Abstract][Full Text] [Related]
36. Influence of
Pujol-Moix N; Martinez-Perez A; Sabater-Lleal M; Llobet D; Vilalta N; Hamsten A; Souto JC; Soria JM
Int J Mol Sci; 2019 Jun; 20(13):. PubMed ID: 31262040
[TBL] [Abstract][Full Text] [Related]
37. Molecular characterization of a unique von Willebrand disease variant. A novel mutation affecting von Willebrand factor/factor VIII interaction.
Cacheris PM; Nichols WC; Ginsburg D
J Biol Chem; 1991 Jul; 266(21):13499-502. PubMed ID: 1906877
[TBL] [Abstract][Full Text] [Related]
38. Variation in baseline factor VIII concentration in a retrospective cohort of mild/moderate hemophilia A patients carrying identical F8 mutations.
Loomans JI; van Velzen AS; Eckhardt CL; Peters M; Mäkipernaa A; Holmstrom M; Brons PP; Dors N; Haya S; Voorberg J; van der Bom JG; Fijnvandraat K
J Thromb Haemost; 2017 Feb; 15(2):246-254. PubMed ID: 27943580
[TBL] [Abstract][Full Text] [Related]
39. Von Willebrand disease type 2N: An update.
Seidizadeh O; Peyvandi F; Mannucci PM
J Thromb Haemost; 2021 Apr; 19(4):909-916. PubMed ID: 33497541
[TBL] [Abstract][Full Text] [Related]
40. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
Michiels JJ; Berneman ZN; van der Planken M; Schroyens W; Budde U; van Vliet HH
Blood Coagul Fibrinolysis; 2004 Jun; 15(4):323-30. PubMed ID: 15166918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
